The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
ORGANIZATION
FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
Japan should hold careful discussions and form a sufficient consensus on what is tentatively called the “drug discovery support fund,” which has been vehemently opposed by US and European pharma groups, Yasushi Okada, chairman of the Federation of Pharmaceutical Manufacturers’…
To read the full story
Related Article
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
- LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
January 28, 2025
- Drug Discovery Fund Not Mentioned in Ruling Party Document; All Eyes on Bill’s Review on Jan. 27
January 24, 2025
- MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting
January 24, 2025
- Nothing Decided on Drug Discovery Support Fund: Minister
January 15, 2025
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
ORGANIZATION
- Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
- EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
January 9, 2026
- FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
- Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
- Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…